
An Unbiased Objective Approach to Report on Significant Research with Public Health Impact

Pranela Rameshwar^{1,*} and Paolo Di Nardo^{2,*}

¹*From Rutgers New Jersey Medical School, Department of Medicine, Newark, NJ 07103 USA*

²*Interdepartmental Center of Regenerative Medicine, University of Rome “Tor Vergata”, Rome, Italy*

E-mail: rameshwa@njms.rutgers.edu; dinardo@uniroma2.it

**Corresponding Author*

The *International Journal of Translational Science* (IJTS) was inaugurated in 2015 with outstanding peer-reviewed manuscripts. Due to unforeseen circumstances, IJTS was placed on ‘hold’. We are pleased to work with River Publisher to relaunch the journal with a strong diverse editorial team with broad scientific backgrounds. The editorial board includes experts in basic and clinical sciences with backgrounds ranging from tissue engineering to material science, additive manufacturing, experimental medicine, aging, clinical trials, cell therapy, oncology, and maternal fetal medicine. Thus, the editorial board members are prepared for submissions of inter- and multi-disciplinary research studies to fulfill the journal’s goal. The journal aims to provide scientists and trainees as well as healthcare personnel with a platform that shares basic and clinical research, including submissions of translational science. Together, the broad types of submission could serve as a platform to develop research studies that will hasten scientific findings to patients. In this regard, the papers would benefit scientists in academia, biotechnology and pharmaceutical companies, professionals, and experts committed to design novel diagnostic and therapeutic strategies.

The goals will be achieved with publications describing research studies that are inter- and multi-disciplinary. We will encourage publications in multiple scientific fields, as focused studies and new sciences that incorporate

multiple disciplines. The latter could include the subjects of biomaterials, engineering, bioprinting, regenerative medicine, stem cell, aging, cancer and hematopoiesis. More importantly, we intend to reach patients and healthcare personnel, particularly for articles pertaining to early breakthroughs on clinical trials. This latter area will circumvent the long process that stakeholders wait for the outcome of innovative clinical outcomes.

Studies on biomaterials are included in this translational journal to facilitate models to enhance 2-dimensional studies for the purpose of narrowing the optimal conditions of particular scientific questions. We will encourage papers on healthy aging but will incorporate studies linked to aging such as cancer. Papers on hematopoiesis will be expanded to studies on the immune system since the former is the source of immune cell development. Regenerative medicine will be enhanced by the aforementioned describe topics, and additionally also include models with bioprinting, organoids and extensive imaging to recapitulate the physiological systems. The interdisciplinary focus of the journal will demonstrate that a network of scientific disciplines will bring closer insights into physiological processes, and serves as models for young scientists to incorporate other scientific disciplines in their research hypotheses.

Publications on clinical trials will be accompanied with lay abstracts for patient education. To this end, the editorial team will be actively seeking the appropriate time to report on breakthrough clinical findings. These reports will make it clear to the readers that the data are derived at an early phase. The journal will inform readers of the stage of the clinical data, such as patient enrollment, insufficient data analyses and questions about the significance to ethnic diversity. These publications will allow stakeholders such as the patients and healthcare providers to be aware of new clinical breakthroughs with the potential to become standard treatments. The publisher, along with the editors and editorial board, will clarify that the report is preliminary. They will make it clear to the readers that the outcome from the final trials with increased patient enrollment may change the results.

Our priority is to respect all submissions since members of the team are aware that authors have placed considerable time and effort to prepare articles, and to acquire primary data to test novel hypothesis. We will consider manuscripts with scientific rigor and reproducible data, and those that adhere to stringent ethics. The publisher and editors will ensure authors that their manuscript will be fairly reviewed by qualified peers without conflict of interest. More importantly, all manuscripts will be considered solely based on merit rather than academic institution or the authors' scientific

reputation. We will enhance the time between submission and acceptance to allow authors to disseminate their findings, without delay. This will facilitate authors who are interested in rapid publication to support grant submission, and/or academic promotion.

The global editorial team members are diverse and inclusive. In addition to the techniques outlined in the Materials and Method section, the journal will make it easy for other scientists to reproduce the data with detailed step-by-step methods of the techniques. These detailed methods will be published in *River Methods*. We will invite authors of accepted papers to submit the detailed protocols, which will be reviewed by members of the editorial board.

In addition to articles with primary data, the journal encourages submission of review articles, commentary, case report, and letters to report early findings. The journal will partner with specific scientific meetings for selected publications. We also encourage guest editors for issues of special topics within the goals and objectives of the journal. Overall, *IJTS* is expected to fill a gap where authors will have an unbiased platform to publish their research and to report on review articles.

